Arthur Sands, Nurix Therapeutics CEO
Seagen teams up with protein degradation specialist to make a new kind of antibody conjugate, paying $60M upfront
Seagen, whose suite of antibody-drug conjugates enticed Pfizer to a $43 billion buyout, is looking to put a twist on the idea.
The Seattle-based drugmaker …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
